Literature DB >> 26957957

Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis.

Bulent Yilmaz1, Seyfettin Koklu2, Huseyin Buyukbayram3, Kendal Yalçin4, Ugur Korkmaz5, Emrah Posul6, Guray Can6, Mevlut Kurt6.   

Abstract

BACKGROUND: The effect of hepatitis B virus (HBV) infection on fatty liver disease is unclear.
OBJECTIVES: The aim of this study was to investigate the viral and host causes of fatty liver in chronic hepatitis B (CHB) patients. This study included 88 CHB patients of which 17 were not treated. Liver biopsy was performed in each patient. Group 1 included those with hepatic steatosis (n=28) and group 2 those without hepatic steatosis. The groups were compared in terms of age, body mass index (BMI), Homeostasis Model Assessment- Insulin Resistance (HOMA-IR), viral load, biochemical parameters and histological findings. Patients in group 1 were subdivided according to the degree of steatosis as follows: grade 1 (15 patients, 53.6%), grade 2 (6 patients, 21.4%), and grade 3 (7 patients, 25%).
RESULTS: In group 1 (n=28), mean age, BMI, cholesterol, and HOMA-IR were found to be significantly higher than in group 2 (n=60). There were no significant differences in the positivity of viral load, HbeAg, treatment, fibrosis and other laboratory parameters between the two groups. HOMA-IR was the only independent predictive factor of liver steatosis in patients with CHB in logistic regression analysis.
CONCLUSION: Hepatic steatosis in CHB patients was associated with host metabolic factors.

Entities:  

Keywords:  BMI; Chronic hepatitis B; HOMA-IR; biopsy; liver steatosis

Mesh:

Substances:

Year:  2015        PMID: 26957957      PMCID: PMC4765474          DOI: 10.4314/ahs.v15i3.3

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  23 in total

Review 1.  Hepatitis C and steatosis: a reappraisal.

Authors:  A Lonardo; P Loria; L E Adinolfi; N Carulli; G Ruggiero
Journal:  J Viral Hepat       Date:  2006-02       Impact factor: 3.728

2.  Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity.

Authors:  Laurentius A Lesmana; C Rinaldi Lesmana; Levina S Pakasi; Ening Krisnuhoni
Journal:  Acta Med Indones       Date:  2012-01

3.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

4.  Impact of non-alcoholic fatty liver disease on chronic hepatitis B.

Authors:  Silvia Bondini; Jillian Kallman; Angela Wheeler; Shivaani Prakash; Terry Gramlich; Daniel M Jondle; Zobair M Younossi
Journal:  Liver Int       Date:  2007-06       Impact factor: 5.828

5.  Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma.

Authors:  Kook Hwan Kim; Hye-Jun Shin; Kyeongjin Kim; Hyun Mi Choi; Sang Hoon Rhee; Hyung-Bae Moon; Hyeong Hoe Kim; Ung Suk Yang; Dae-Yeul Yu; Jaehun Cheong
Journal:  Gastroenterology       Date:  2007-03-24       Impact factor: 22.682

6.  Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

Authors:  Jason M Hui; James G Kench; Shivakumar Chitturi; Archana Sud; Geoffrey C Farrell; Karen Byth; Pauline Hall; Mahbub Khan; Jacob George
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

7.  Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis.

Authors:  Chia-Chi Wang; Ching-Sheng Hsu; Chun-Jen Liu; Jia-Horng Kao; Ding-Shinn Chen
Journal:  J Gastroenterol Hepatol       Date:  2007-11-19       Impact factor: 4.029

8.  Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis.

Authors:  A J Czaja; H A Carpenter
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

9.  Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C.

Authors:  E Tsochatzis; G V Papatheodoridis; E K Manesis; N Chrysanthos; G Kafiri; A J Archimandritis
Journal:  Dig Liver Dis       Date:  2007-08-27       Impact factor: 4.088

10.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

View more
  8 in total

Review 1.  Hepatocellular carcinoma and non-alcoholic fatty liver disease.

Authors:  Pegah Golabi; Logan Rhea; Linda Henry; Zobair M Younossi
Journal:  Hepatol Int       Date:  2019-11-07       Impact factor: 6.047

2.  Interleukin-17F expression is elevated in hepatitis C patients with fibrosis and hepatocellular carcinoma.

Authors:  Ming-Sian Wu; Chun-Hsiang Wang; Fan-Chen Tseng; Hsuan-Ju Yang; Yin-Chiu Lo; Yi-Ping Kuo; De-Jiun Tsai; Wan-Ting Tsai; Guann-Yi Yu
Journal:  Infect Agent Cancer       Date:  2017-07-26       Impact factor: 2.965

3.  PNPLA3 rs1010023 Predisposes Chronic Hepatitis B to Hepatic Steatosis but Improves Insulin Resistance and Glucose Metabolism.

Authors:  Qin Pan; Mei-Mei Chen; Rui-Nan Zhang; Yu-Qin Wang; Rui-Dan Zheng; Yu-Qiang Mi; Wen-Bin Liu; Feng Shen; Qing Su; Jian-Gao Fan
Journal:  J Diabetes Res       Date:  2017-06-14       Impact factor: 4.011

4.  Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma.

Authors:  Pei-Song Bai; Nan Xia; Hong Sun; Ying Kong
Journal:  J Cell Mol Med       Date:  2017-05-30       Impact factor: 5.310

5.  Diagnostic efficacy of FibroScan for liver inflammation in patients with chronic hepatitis B: a single-center study with 1185 liver biopsies as controls.

Authors:  Kaiping Jiang; Lei Zhang; Jianhong Li; Hongtao Hu; Qinghua Huang; Tengyu Qiu; Xiaoai Mo; Jian Ren; Wenqiang Guo; Yin Tao; Haijun Cui; Ying Zuo; Xuli Chen; Youqing Xie; Yanxing Li; Haimin Liang; Zhaohong Liu; Le Xie; Rongjun Mao; Qunfang Jiang; Kaizhou Huang
Journal:  BMC Gastroenterol       Date:  2022-01-29       Impact factor: 3.067

Review 6.  Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era.

Authors:  Heather L Stevenson; Netanya S Utay
Journal:  Trop Dis Travel Med Vaccines       Date:  2016-09-27

7.  Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B.

Authors:  Juan Li; Auke P Verhaar; Qiuwei Pan; Robert Jacobus de Knegt; Maikel P Peppelenbosch
Journal:  Clin Exp Gastroenterol       Date:  2017-08-11

8.  Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients.

Authors:  Qun-Yan Yao; Ya-Dong Feng; Pei Han; Feng Yang; Guang-Qi Song
Journal:  World J Gastroenterol       Date:  2020-07-21       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.